Brief Rapid Communication

Selective Endothelin-A Versus Combined Endothelin-A/Endothelin-B Receptor Blockade in Rat Chronic Heart Failure

Paul Mulder, PhD; Houssaine Boujedaini, BS; Vincent Richard, PhD; Genevieve Derumeaux, MD, PhD; Jean Paul Henry; Sylvanie Renet; Jerry Wessale, PhD; Terry Oppenorth, PhD; Christian Thuillez, MD, PhD

Background—The relative efficacy of endothelin-A (ET\textsubscript{A}) receptor blockade versus combined ET\textsubscript{A}-ET\textsubscript{B} receptor blockade in chronic heart failure (CHF) is still largely unknown.

Methods and Results—We compared, in a rat model of CHF (coronary ligation), the hemodynamic and structural effects of 1 month of treatment with the ET\textsubscript{A} antagonist ABT-627 (5 mg \cdot kg\textsuperscript{-1} \cdot d\textsuperscript{-1}), the ET\textsubscript{B} antagonist A-192621 (30 mg \cdot kg\textsuperscript{-1} \cdot d\textsuperscript{-1}) or a combination of the 2 drugs. Doses were chosen for their capacity to block the pressor response to ET-1 (for ET\textsubscript{A} blockade) or the depressor responses to sarafotoxin S6c or ET-1 (for ET\textsubscript{B} blockade). ET\textsubscript{A} and combined ET\textsubscript{A}-ET\textsubscript{B} blockade reduced systolic blood pressure to the same extent, whereas ET\textsubscript{B} blockade had no effect. In contrast, only combined ET\textsubscript{A}-ET\textsubscript{B} blockade significantly reduced heart rate. Both ET\textsubscript{A} and combined ET\textsubscript{A}-ET\textsubscript{B} blockade, but not ET\textsubscript{B} blockade alone, increased left ventricular (LV) fractional shortening and wall thickening and reduced LV end-diastolic pressure, as well as LV end-diastolic and end-systolic volumes. However, all treatments (including ET\textsubscript{B} blockade) decreased LV collagen accumulation.

Conclusions—The chronic blockade of both ET\textsubscript{A} and ET\textsubscript{B} receptors improved systemic hemodynamics, as well as LV function and remodeling, to the same extent as ET\textsubscript{A} receptor blockade alone. However, only combined ET\textsubscript{A}-ET\textsubscript{B} receptor blockade decreased heart rate. Whether this differential effect on heart rate affects the long-term outcome after treatment with ET\textsubscript{A} or mixed ET\textsubscript{A}-ET\textsubscript{B} antagonists in CHF remains to be determined. (Circulation. 2000;102:491-493.)

Key Words: endothelin ■ heart failure ■ heart rate ■ remodeling

Mixed endothelin A–endothelin B receptor (ET\textsubscript{A}-ET\textsubscript{B}) antagonists exert beneficial effects in experimental chronic heart failure (CHF),\textsuperscript{1} but selective ET\textsubscript{A} antagonists have been shown to be either beneficial\textsuperscript{2–4} or deleterious.\textsuperscript{5,6} However, to date, no study has compared the efficacy of these 2 pharmacological approaches to CHF. Thus, whether simultaneous blockade of ET\textsubscript{A} receptors will reinforce or reduce the efficacy of ET\textsubscript{B} antagonists in CHF is still unknown. Moreover, the effects of chronic ET\textsubscript{B} blockade per se are also unknown. In theory, the blockade of ET\textsubscript{B} receptors may have deleterious effects by reducing the ET\textsubscript{B}-mediated endothelin-dependent vasodilatation or by decreasing clearance and, thus, increasing plasma levels of ET. We compared the effect of a selective ET\textsubscript{A} antagonist, a selective ET\textsubscript{B} antagonist, or a combination of the 2 antagonists in rat model of CHF.

Methods

CHF was induced by myocardial infarction, as described previously.\textsuperscript{1} Eight days after surgery, the animals were randomized to 1 of the following 5 groups (n=12 per group): sham, CHF untreated, CHF plus ABT-627 (ET\textsubscript{A} antagonist; 5 mg \cdot kg\textsuperscript{-1} \cdot d\textsuperscript{-1}), CHF plus A-192621 (ET\textsubscript{B} antagonist; 30 mg \cdot kg\textsuperscript{-1} \cdot d\textsuperscript{-1}), and CHF plus a combination of ABT-627 and A-192621. All treatments were administered as a food additive for 4 weeks. The dose of ABT-627 was chosen because it blocked the ET\textsubscript{A}-mediated sustained vasoconstriction to ET-1 without affecting ET\textsubscript{B}-mediated transient vasodilatation,\textsuperscript{7} whereas that of A192621 was the smallest dose that completely blocked ET-1–induced transient vasodilatation without affecting sustained vasoconstriction.\textsuperscript{8} To verify long-term ET receptor blockade, the effects of intravenous bolus injections of ET-1 (1 nmol/kg) and sarafotoxin S6c (0.3 ng/kg) were assessed after 4 weeks of treatment in randomly selected animals from each group.

Systolic blood pressure and heart rate were determined in conscious rats (plethysmography) just before the start of treatment (7 days after ligation) and after 4 weeks of treatment. Transthoracic Doppler echocardiographic studies were performed in anesthetized rats; arterial pressure and left ventricular (LV) systolic and end-diastolic pressures and dP/dt\textsubscript{max} were measured as described previously.\textsuperscript{1} Before euthanization, a blood sample was taken through the carotid artery to determine plasma ET-1 levels (by ELISA).

All values are given as means±SEM. Differences were compared by \textit{t} test or by ANOVA followed by a Tukey test for multiple comparisons. They were considered significant at \(P<0.05\).
Results

**ET\textsubscript{A}-ET\textsubscript{B} Receptor Blockade**

After 4 weeks of treatment, the ET\textsubscript{A} antagonist did not modify the decrease in blood pressure to sarafotoxin S6c or the transient depressor response to ET-1, but it markedly decreased the sustained pressor response to ET-1. The ET\textsubscript{B} antagonist decreased the response to sarafotoxin S6c and the transient depressor effect of ET-1, but it did not affect the sustained pressor response to ET-1. Combined ET\textsubscript{A}-ET\textsubscript{B} treatment reduced the sustained pressor response to ET-1 to the same extent as ET\textsubscript{A} blockade alone and decreased the response to sarafotoxin S6c and the transient depressor effect of ET-1 to the same extent as ET\textsubscript{B} blockade alone (Table 1).

**Systemic Hemodynamics**

After 4 weeks of treatment in CHF rats, ET\textsubscript{A} blockade and combined ET\textsubscript{A}-ET\textsubscript{B} blockade decreased systolic blood pressure significantly and to the same extent, whereas the ET\textsubscript{B} antagonist treatment had no effect (Figure 1). Both the ET\textsubscript{A} and the ET\textsubscript{B} antagonist tended to reduce heart rate. However, a more marked, significant decrease in heart rate was observed after the coadministration of ET\textsubscript{A} and ET\textsubscript{B} antagonists (Figure 1).

**Cardiac Functional Parameters and Remodeling**

Compared with untreated CHF rats, ET\textsubscript{A} and combined ET\textsubscript{A}-ET\textsubscript{B} blockade (but not ET\textsubscript{B} blockade) reduced LV systolic pressure and LV end-diastolic pressure to the same extent, without affecting LV dP/dt\textsubscript{max} (Figure 1).

Echocardiographic studies (Figure 2) show that ET\textsubscript{A} blockade increased LV fractional shortening and LV posterior wall thickening, whereas the ET\textsubscript{B} antagonist did not affect these parameters. Coadministration of the selective ET\textsubscript{A} and the selective ET\textsubscript{B} antagonist increased both LV fractional shortening and LV posterior wall thickening to the same extent as treatment with the ET\textsubscript{A} antagonist alone.

The ET\textsubscript{A} antagonist limited the progressive increase of LV end-diastolic diameter, but the ET\textsubscript{B} antagonist did not affect this parameter. Coadministration of the ET\textsubscript{A} and the ET\textsubscript{B} antagonist decreased LV end-diastolic diameter to the same extent as treatment with the ET\textsubscript{A} antagonist alone (Figure 2).

**Plasma ET-1 Levels**

Compared with sham animals, plasma levels of ET-1 were increased in CHF animals (7 ± 1 and 13 ± 3 fmol/mL, respectively; \(P<0.05\)). ET\textsubscript{A}, ET\textsubscript{B}, or combined ET\textsubscript{A}-ET\textsubscript{B} blockade did not affect the levels of ET-1 (13 ± 3, 15 ± 2, and 18 ± 5 fmol/mL, respectively).

**Cardiac Morphology**

Infarct size was not significantly different between the groups (Table 2). Neither treatment affected heart weight or the heart weight to body weight ratio. In contrast, all treatments (ET\textsubscript{A}, ET\textsubscript{B}, or combined ET\textsubscript{A}-ET\textsubscript{B} blockade) decreased LV collagen density significantly and to the same extent (Table 2).

**Discussion**

The main results of our study, which was performed using a rat model of CHF, are as follows. (1) Chronic, simultaneous blockade of both ET\textsubscript{A} and ET\textsubscript{B} receptors improved systemic and cardiac hemodynamics, as well as LV function and remodeling, to the same extent as ET\textsubscript{A} receptor blockade alone. However, these effects were associated with a significant reduction of heart rate only with simultaneous ET\textsubscript{A}-ET\textsubscript{B} receptor blockade. (2) Chronic, selective ET\textsubscript{B} receptor blockade per se did not affect systemic and cardiac hemodynamics, nor the LV dilation of CHF animals, but it did reduce LV collagen density.

---

**Table 1. Changes in Blood Pressure Induced by Intravenous Injection of ET-1 and Sarafotoxin S6c**

<table>
<thead>
<tr>
<th></th>
<th>Sham</th>
<th>Control</th>
<th>ET\textsubscript{A}-Treated</th>
<th>ET\textsubscript{B}-Treated</th>
<th>ET\textsubscript{A}+ET\textsubscript{B}-Treated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sarafotoxin S6c</td>
<td>-16.5±4.3</td>
<td>-21.2±3.9</td>
<td>-15.6±6.7</td>
<td>-6.9±1.0*</td>
<td>-8.7±1.6*</td>
</tr>
<tr>
<td>ET-1</td>
<td>Transient dilatation</td>
<td>-40.6±3.0</td>
<td>-34.8±3.5</td>
<td>-36.1±4.3</td>
<td>-7.6±3.9*</td>
</tr>
<tr>
<td></td>
<td>Sustained constriction</td>
<td>21.8±10.0</td>
<td>21.2±2.1</td>
<td>9.7±2.0*</td>
<td>25.8±6.8</td>
</tr>
</tbody>
</table>

\*\(P<0.05\) vs CHF control.

---

**Figure 1.** Systolic blood pressure (SBP), heart rate (HR), LV end-diastolic pressure (LVEDP), and LV dP/dt\textsubscript{max} as determined in anesthetized rats with CHF after 4 weeks of no treatment (white bars) or treatment with ABT-627 (up-hatched bars), A192621 (solid bars), or a combination of the 2 drugs (down-hatched bars). \*\(P<0.05\) vs untreated CHF.

**Figure 2.** LV end-diastolic diameter (LVEDD), LV fractional shortening (FS), and LV posterior wall thickening (PWTh), as determined in anesthetized rats with CHF after 4 weeks of no treatment (white bars) or treatment with ABT-627 (up-hatched bars), A192621 (solid bars), or a combination of the 2 drugs (down-hatched bars). \*\(P<0.05\) vs untreated CHF.
TABLE 2. Cardiac Morphology in the Different Groups after 4 Weeks of Treatment

<table>
<thead>
<tr>
<th></th>
<th>Sham</th>
<th>Control</th>
<th>ET_{A}-Treated</th>
<th>ET_{B}-Treated</th>
<th>ET_{A}+ET_{B}-Treated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infarct size, %</td>
<td>—</td>
<td>47.3</td>
<td>42.4</td>
<td>46.3</td>
<td>46.6</td>
</tr>
<tr>
<td>LV collagen, %</td>
<td>3.2±0.3^*</td>
<td>5.8±0.4</td>
<td>4.1±0.2^*</td>
<td>3.7±0.2^*</td>
<td>3.7±0.1^*</td>
</tr>
<tr>
<td>Heart weight, g</td>
<td>1.05±0.06^*</td>
<td>1.27±0.06</td>
<td>1.26±0.03</td>
<td>1.22±0.06</td>
<td>1.22±0.03</td>
</tr>
</tbody>
</table>

^*P<0.05 vs CHF control.

Effect of ET_{B} Receptor Blockade

After 1 month of treatment, the ET_{B} antagonist did not alter blood pressure, suggesting the absence of ET_{B}-mediated vasoconstriction in CHF. However, whether these differences in terms of heart rate reduction affect the long-term outcome of the treatments for CHF cannot be answered from the present study.

Acknowledgments

The authors thank Eliane Abdelhouab for her excellent assistance and Abbott Laboratories for providing the ET antagonists.

References


Selective Endothelin-A Versus Combined Endothelin-A/Endothelin-B Receptor Blockade in Rat Chronic Heart Failure

_Circulation_. 2000;102:491-493
doi: 10.1161/01.CIR.102.5.491

_Circulation_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2000 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/102/5/491

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation_ is online at:
http://circ.ahajournals.org//subscriptions/